PDS Biotechnology Corp (PDSB) reports reduced net loss and operating expenses while advancing promising clinical trials and strengthening its intellectual property portfolio.

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2025 Earnings Call Transcript March 30, 2026 PDS Biotechnology Corporation ...

Adopting millets isn't a nostalgic return to the past. It is about meeting today's nutritional and ecological challenges with ...

A three-sport athlete at Princeton High, Bornstein, who is just five-feet tall, plays with an amazing measure of heart and ...

Q4 2025 Management View Frank Bedu-Addo, President, CEO & Director, detailed that "the fourth quarter of 2025 capped a period of important progress for PDS Biotech, marked by meaningful advances ...

Ever since the end of January, the National Tertiary Education Union (NTEU) has touted a vague “in-principle” agreement at ...

In this episode of Investing Compass, Mark and Shani run through the tilts in passive investments and how that exposure impacts investors.

Kerosene, once widely subsidised and used in India, was phased out with LPG expansion; now, amid global supply disruptions, ...

Star sprinter Animesh Kujur of Odisha won the 100m dash in a photo finish after earlier clinching the 200m title, stealing ...

Rates markets are worried about risks to inflation, although central banks will ultimately balance both inflation and ...

Leading brands, including Walmart, have signed letters of support for unspun's plan to build domestic manufacturing capacity in the U.S. using an AI-enabled 3D weaving technology ...

The Extreme Poverty Eradication Programme was positioned as a radical step by the Pinarayi government. Despite its efficient ...